Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

Next Previous
Trial Profile

Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms AVERT

    • Most Recent Events

    • 12 Dec 2023 Results of a post-hoc analysis assessing performance of available risk prediction scores for anticoagulant-related bleeding in cancer patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 01 Aug 2023 Results of post hoc analysis assessing the influence of inherited thrombophilia on VTE and bleeding risk in moderate-high risk ambulatory cancer patients receiving chemotherapy published in the Journal of Thrombosis and Haemostasis
    • 14 Dec 2021 Results of a post hoc analysis assessing the efficacy and safety of apixaban thromboprophylaxis according to renal function at randomization presented at the 63rd American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top